Antibody Drug Conjugates Market By Drug ( Adcetris, Kadcyla ), By Mechanism of Action ( CD30 Antibodies, HER2 Antibodies ), By Application ( Lymphoma, Breast cancer ), Industry Trends, Estimation & Forecast, 2017 - 2025

Check Today's Best Price

$3500 Buy Now
Antibody Drug Conjugates Market is expected to generate $3.2 Billion by the end of 2025.
  • Market Overview:

    The global antibody drug conjugates market is growing at rapid pace due to increase in number of cancer patients worldwide. However, the market is in infancy stage as only two drugs are being marketed and several ADCs are under last stages of its clinical development. These marketed ADCs target different forms of cancers such as lymphoma and breast cancer. It is predicted that ADCs under development would be able to treat lung cancer, breast cancer, melanoma, and Hodgkin’s lymphoma in the future. Currently, players in the market are taking efforts to develop ADCs that target different domains other than oncology.

    Factors such as an increase in consumption in tobacco and alcohol, sedentary lifestyle, and increasing the number of cancer patients across the globe are driving the growth of the market. Moreover, rising awareness among consumer regarding ADC therapy, increasing demand for cost-effective cancer treatment and extensive research and development activities carried by market players boosts market growth. However, high cost involved in the development of ADCs is expected to hinder the growth of the market, whereas, Asia-Pacific shows ample opportunities for ADC developers due to presence of large pool of patients suffering from cancer.

    The report provides detailed qualitative and quantitative analysis of the global antibody drug conjugates market. Market size and forecast in terms of value has been provided for the period – (2017 – 2025), for the segments namely drugs, mechanism of action, and application in each of the major regions of the world.

    Antibody Drug Conjugates Market Segmentation

    By Drug 
    • Adcetris
    • Kadcyla

    By Mechanism of Action
    • CD30 antibodies
    • HER2 antibodies

    By Application
    • Lymphoma
    • Breast cancer
    • Others

    By Geography

    • North America
    o U.S.
    o Canada
    o Mexico

    • Europe
    o U.K
    o France
    o Germany
    o Italy
    o Spain
    o Rest of Europe

    • Asia-Pacific
    o Japan
    o China
    o India
    o Rest of Asia-Pacific

    • Rest of the World
    o Middle East
    o Latin America
    o Africa

    keyboard_arrow_up
  • CHAPTER 1. INTRODUCTION
    1.1. RESEARCH METHODOLOGY
    1.1.1. ERC desk research
    1.1.2. ERC data synthesis
    1.1.3. Data validation and market feedback
    1.1.4. ERC data sources

    CHAPTER 2. ANTIBODY DRUG CONJUGATES MARKET OVERVIEW
    2.1. ANTIBODY DRUG CONJUGATES MARKET INTRODUCTION
    2.2. GLOBAL ANTIBODY DRUG CONJUGATES MARKET REVENUE AND GROWTH RATE, 2017-2025
    2.2.1. Global Antibody Drug Conjugates Market Revenue (Million USD) and Growth Rate (%), (2017-2025)

    CHAPTER 3. GLOBAL ANTIBODY DRUG CONJUGATES MARKET BY DRUG, 2017-2025
    3.1. ADCETRIS
    3.2. KADCYLA
    3.3. GLOBAL ANTIBODY DRUG CONJUGATES MARKET REVENUE BY DRUG, 2017-2025
    3.3.1. Global Antibody Drug Conjugates Market Revenue (Million USD) and Share (%) By Drug, 2017-2025
    3.3.2. Adcetris Market Revenue and Growth Rate, 2017-2025
    3.3.3. Kadcyla Market Revenue and Growth Rate, 2017-2025

    Note: Similar information coverage has been provided for by mechanism of action segment.

    CHAPTER 4. GLOBAL ANTIBODY DRUG CONJUGATES MARKET BY APPLICATION, 2017-2025
    4.1. LYMPHOMA
    4.2. BREAST CANCER
    4.3. OTHERS
    4.4. GLOBAL ANTIBODY DRUG CONJUGATES MARKET REVENUE BY APPLICATION, 2017-2025
    4.4.1. Global Antibody Drug Conjugates Market Revenue (Million USD) and Share (%) By Application, 2017-2025
    4.4.2. Lymphoma Market Revenue and Growth Rate, 2017-2025
    4.4.3. Breast cancer Market Revenue and Growth Rate, 2017-2025
    4.4.4. Others Market Revenue and Growth Rate, 2017-2025

    CHAPTER 5. GLOBAL ANTIBODY DRUG CONJUGATES MARKET BY REGION, 2017-2025
    5.1. NORTH AMERICA
    5.1.1. U.S.
    5.1.2. Canada
    5.1.3. Mexico
    5.2. EUROPE
    5.2.1. U.K.
    5.2.2. France
    5.2.3. Germany
    5.2.4. Italy
    5.2.5. Spain
    5.2.6. Rest of Europe
    5.3. ASIA PACIFIC
    5.3.1. China
    5.3.2. Japan
    5.3.3. India
    5.3.4. Korea
    5.3.5. Rest of APAC
    5.4. SOUTH AMERICA
    5.4.1. Brazil
    5.4.2. Rest of South America
    5.5. REST OF THE WORLD
    5.5.1. Middle East
    5.5.2. Africa
    5.6. GLOBAL ANTIBODY DRUG CONJUGATES MARKET REVENUE BY REGION, 2017-2025
    5.6.1. Global Antibody Drug Conjugates Market Revenue (Million USD) and Share (%) By Region, 2017-2025
    5.6.2. North America Market Revenue and Growth Rate, 2017-2025
    5.6.3. Europe Market Revenue and Growth Rate, 2017-2025
    5.6.4. Asia Pacific Market Revenue and Growth Rate, 2017-2025
    5.6.5. South America Market Revenue and Growth Rate, 2017-2025
    5.6.6. Rest of the World Market Revenue and Growth Rate, 2017-2025

    CHAPTER 6. MARKET DETERMINANTS
    6.1. MARKET DRIVERS
    6.2. MARKET RESTRAINTS
    6.3. MARKET OPPORTUNITIES
    6.4. MARKET DETERMINANTS RADAR CHART

    CHAPTER 7. GLOBAL ANTIBODY DRUG CONJUGATES MARKET COMPETITION BY SERVICE PROVIDERS
    7.1. GLOBAL ANTIBODY DRUG CONJUGATES REVENUE AND SHARE BY SERVICE PROVIDERS (2017-2025)
    7.1.1. Global Antibody Drug Conjugates Revenue (Million USD) and Share (%) by Service Providers (2017-2025)
    7.2. ANTIBODY DRUG CONJUGATES MARKET COMPETITIVE SITUATION AND TRENDS
    7.2.1. Antibody Drug Conjugates Market Share (%) of Top 3 Service Providers
    7.2.2. Antibody Drug Conjugates Market Share (%) of Top 5 Service Providers

    CHAPTER 8. COMPANY PROFILES
    8.1. SEATTLE GENETICS INC.
    8.1.1. Business Overview
    8.1.2. Company Basic Information
    8.1.3. Antibody Drug Conjugates Product Details
    8.1.4. Seattle Genetics Inc. Antibody Drug Conjugates Revenue and Gross Margin
    8.2. ROCHE HOLDING AG
    8.2.1. Business Overview
    8.2.2. Company Basic Information
    8.2.3. Antibody Drug Conjugates Product Details
    8.2.4. Roche Holding AG Antibody Drug Conjugates Revenue and Gross Margin
    8.3. IMMUNOGEN, INC.
    8.3.1. Business Overview
    8.3.2. Company Basic Information
    8.3.3. Antibody Drug Conjugates Product Details
    8.3.4. ImmunoGen, Inc. Antibody Drug Conjugates Revenue and Gross Margin
    8.4. GENENTECH INC.
    8.4.1. Business Overview
    8.4.2. Company Basic Information
    8.4.3. Antibody Drug Conjugates Product Details
    8.4.4. Genentech Inc. Antibody Drug Conjugates Revenue and Gross Margin
    8.5. AGENSYS, INC.
    8.5.1. Business Overview
    8.5.2. Company Basic Information
    8.5.3. Antibody Drug Conjugates Product Details
    8.5.4. Agensys, Inc. Antibody Drug Conjugates Revenue and Gross Margin
    8.6. BAYER HEALTHCARE PHARMACEUTICALS
    8.6.1. Business Overview
    8.6.2. Company Basic Information
    8.6.3. Antibody Drug Conjugates Product Details
    8.6.4. Bayer Healthcare Pharmaceuticals Antibody Drug Conjugates Revenue and Gross Margin
    8.7. VACCINEX INC.
    8.7.1. Business Overview
    8.7.2. Company Basic Information
    8.7.3. Antibody Drug Conjugates Product Details
    8.7.4. Vaccinex Inc. Antibody Drug Conjugates Revenue and Gross Margin
    8.8. CONCORTIS BIOTHERAPEUTICS
    8.8.1. Business Overview
    8.8.2. Company Basic Information
    8.8.3. Antibody Drug Conjugates Product Details
    8.8.4. Concortis Biotherapeutics Antibody Drug Conjugates Revenue and Gross Margin
    8.9. CELLDEX THERAPEUTICS INC.
    8.9.1. Business Overview
    8.9.2. Company Basic Information
    8.9.3. Antibody Drug Conjugates Product Details
    8.9.4. Celldex Therapeutics Inc. Antibody Drug Conjugates Revenue and Gross Margin
    8.10. DAIICHI SANKYO
    8.10.1. Business Overview
    8.10.2. Company Basic Information
    8.10.3. Antibody Drug Conjugates Product Details
    8.10.4. Daiichi Sankyo Antibody Drug Conjugates Revenue and Gross Margin

    CHAPTER 9. ANTIBODY DRUG CONJUGATES MARKET VALUE CHAIN ANALYSIS
    9.1. ANTIBODY DRUG CONJUGATES INDUSTRIAL CHAIN ANALYSIS
    9.2. CONSUMER ANALYSIS
    9.2.1. Consumer 1
    9.2.2. Consumer 2
    9.2.3. Consumer 3
    9.2.4. Consumer 4

    keyboard_arrow_up
  • • Seattle Genetics Inc.
    • Roche Holding AG
    • ImmunoGen, Inc.
    • Genentech Inc.
    • Agensys, Inc.
    • Bayer Healthcare Pharmaceuticals
    • Vaccinex Inc.
    • Concortis Biotherapeutics
    • Celldex Therapeutics Inc.
    • Daiichi Sankyo

    keyboard_arrow_up


    • Keep your personal detail safe with us. Privacy Policy
      This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

What Information does this report contain?

• What was the market size of the Antibody Drug Conjugates Market in 2017 and the expected market size by 2025, along with the growth rate?
• An in-depth analysis of the current impacting factors, opportunities and challenges/restraints in the market
• Which are the largest revenue generating products, services or regions and their comparative growth rate?
• Which technology is in trend and how would it evolve during the forecast period (2017 – 2025)?
• Which are the leading companies in the Antibody Drug Conjugates Market and their competitive positioning basis their market share, product portfolio, strategic attempts and business focus?

CLIENTS

SHARE YOUR CART